Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Kanerva

Showing results (121-130 of 124) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 124 results.
Frontiers in Immunology|February 23, 2023
Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive settingJames H A Clubb, Tatiana V Kudling, Mykhailo Girych, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 15, 2026
Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumorsElise Jirovec, Katriina J Jalkanen, Dafne C A Quixabeira, et al.
Cancer Immunology Research|January 21, 2026
Ex Vivo Immuno-Oncology Platform Reveals Spatial T Cell Infiltration Patterns Linked to ATR Inhibition Responses in High-Grade Serous Ovarian CancerAshwini Sakrepatna Nagaraj, Matilda Salko, Aditi Sirsikar, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 22, 2026
Dyslipidaemia-associated natural IgM improves oncolytic virus TILT-123 efficacy through antibody-dependent enhancement in solid tumoursJames Hugo Armstrong Clubb, Santeri Artturi Pakola, Sakari Joenväärä, et al.
Pageof 13

Showing results (121-130 of 124) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 124 results.
Frontiers in Immunology|February 23, 2023
Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive settingJames H A Clubb, Tatiana V Kudling, Mykhailo Girych, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 15, 2026
Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumorsElise Jirovec, Katriina J Jalkanen, Dafne C A Quixabeira, et al.
Cancer Immunology Research|January 21, 2026
Ex Vivo Immuno-Oncology Platform Reveals Spatial T Cell Infiltration Patterns Linked to ATR Inhibition Responses in High-Grade Serous Ovarian CancerAshwini Sakrepatna Nagaraj, Matilda Salko, Aditi Sirsikar, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 22, 2026
Dyslipidaemia-associated natural IgM improves oncolytic virus TILT-123 efficacy through antibody-dependent enhancement in solid tumoursJames Hugo Armstrong Clubb, Santeri Artturi Pakola, Sakari Joenväärä, et al.
Pageof 13